MedPacto, Inc.

KOSDAQ 235980.KQ

MedPacto, Inc. Capital Expenditure for the year ending December 31, 2023: USD -132.80 K

MedPacto, Inc. Capital Expenditure is USD -132.80 K for the year ending December 31, 2023, a 81.83% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

MedPacto, Inc. Capital Expenditure for the year ending December 31, 2022 was USD -730.78 K, a 3.94% change year over year.
MedPacto, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -760.72 K, a -2.16% change year over year.
MedPacto, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -744.66 K, a 67.73% change year over year.
MedPacto, Inc. Capital Expenditure for the year ending December 31, 2019 was USD -2.31 M, a -242.13% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KOSDAQ: 235980.KQ

MedPacto, Inc.

CEO	Mr. Seong-Jin Kim
IPO Date	Dec. 19, 2019
Location	South Korea
Headquarters	Borim Building
Employees	57
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

Key trends

Past 5 years